Framebased-Frameless_DV_2017_final.pptx

Previous Page

Next Page

Page Background

Radiosensitizing chemotherapy

GBM

HNC

RT +/- concurrent cisplatin

RT +/- concurrent temozolomide

30 x 2Gy

30 x 2Gy

5 x 6Gy

5 x 6Gy

Ohri et al: IJROBP 2012; 83 (1): 385